Form 4 for PTGX Protagonist Therapeutics, Inc
Accepted 2026-01-27 00:00:00 ET · period of report 2026-01-27 · accession 0001104659-26-007128 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-01-27 | 2026-01-27 | PTGX | Ali Asif | CFO | M - OptEx | $16.18 | +28.0K | 94.5K | +42% | +$453.1K |
| DM | 2026-01-27 | 2026-01-27 | PTGX | Ali Asif | CFO | S - Sale+OE | $83.13 | -46.2K | 60.3K | -43% | -$3.84M |
| DM | 2026-01-27 | 2026-01-27 | PTGX | Ali Asif | CFO | M - OptEx | $0.00 | -28.0K | 18.5K | -60% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-27 | M | A | 12,000 | $12.17 | 106,523 | D | — | — | |
| 2 | Common | Common Stock | 2026-01-27 | M | A | 16,000 | $19.19 | 94,523 | D | — | — | (F1) Includes an aggregate of 446 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2025. |
| 3 | Common | Common Stock | 2026-01-27 | S | D | 28,000 | $83.13 | 78,523 | D | — | — | (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.77 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 4 | Common | Common Stock | 2026-01-27 | S | D | 18,203 | $83.14 | 60,320 | D | — | — | (F3) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $82.80 to $83.595. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 5 | Derivative | Stock Option (right to buy) | 2026-01-27 | M | D | 16,000 | $0.00 | 50,800 | D | $19.19 · — to 2032-04-18 | 16,000 Common Stock | (F4) The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer. |
| 6 | Derivative | Stock Option (right to buy) | 2026-01-27 | M | D | 12,000 | $0.00 | 18,547 | D | $12.17 · — to 2033-01-15 | 12,000 Common Stock | (F5) The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer. |